Sandbox Reserved 972

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 20: Line 20:
==Bradykinin==
==Bradykinin==
-
<scene name='60/604491/Bradykinin/1'>Bradykinin</scene> is a short lived vasoactive nonapeptide mediator of the family of kinins. It's secreted in response to an inflammatory envent and serves as a mediator of pain, inflammation and vasodilatation. It is secreted by the enzymatic action of kallikreins on kininogen precursors<ref>PMID: PMC2658795</ref>. Kallidin is a produt of the enzymatic action of kallikrein to kininogens. Then Kallidin is transformed into bradykinin
+
<scene name='60/604491/Bradykinin/1'>Bradykinin</scene> is a short lived vasoactive nonapeptide mediator of the family of kinins. It's secreted in response to an inflammatory envent and serves as a mediator of pain, inflammation and vasodilatation. It is secreted by the enzymatic action of kallikreins on kininogen precursors. Kallidin is a produt of the enzymatic action of kallikrein to kininogens. Then Kallidin is transformed into bradykinin
Today, we know that kinins can be degraded by IDE.
Today, we know that kinins can be degraded by IDE.
Line 36: Line 36:
==Hypothetical role of bradykinin on IDE==
==Hypothetical role of bradykinin on IDE==
-
Bradykinin is well known as an activator of IDE (34). Consequently, the binding of one bradykinin at the exosite must have an influence on the binding of other substrates. Actually, small peptides like bradykinin can reduce the catalytic chamber by the binding to the exosite. This leads to an increase of the binding of other substrates and the subsequent cleavage by IDE. Alternatively, bradykinin binding could reduce the cleavage by interfering with substrate binding<ref></ref>.
+
Bradykinin is well known as an activator of IDE (34). Consequently, the binding of one bradykinin at the exosite must have an influence on the binding of other substrates. Actually, small peptides like bradykinin can reduce the catalytic chamber by the binding to the exosite. This leads to an increase of the binding of other substrates and the subsequent cleavage by IDE. Alternatively, bradykinin binding could reduce the cleavage by interfering with substrate binding.
Today, we can supposed that binding of bradykinin at the exosite stimulated the conformationnal change of IDE, from its open to its close state. Binding of bradykinin or other short peptides to the exosite could play a regulatory role in substrate binding and cleavage by IDE<ref>doi: 10.1021/bi801192h</ref>.
Today, we can supposed that binding of bradykinin at the exosite stimulated the conformationnal change of IDE, from its open to its close state. Binding of bradykinin or other short peptides to the exosite could play a regulatory role in substrate binding and cleavage by IDE<ref>doi: 10.1021/bi801192h</ref>.

Revision as of 22:35, 9 January 2015

This Sandbox is Reserved from 15/11/2014, through 15/05/2015 for use in the course "Biomolecule" taught by Bruno Kieffer at the Strasbourg University. This reservation includes Sandbox Reserved 951 through Sandbox Reserved 975.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem. 2007 Aug 31;282(35):25453-63. Epub 2007 Jul 5. PMID:17613531 doi:10.1074/jbc.M701590200
  2. Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221 doi:10.1038/nature05143
  3. Song ES, Juliano MA, Juliano L, Hersh LB. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J Biol Chem. 2003 Dec 12;278(50):49789-94. Epub 2003 Oct 2. PMID:14527953 doi:http://dx.doi.org/10.1074/jbc.M308983200
  4. Malito E, Ralat LA, Manolopoulou M, Tsay JL, Wadlington NL, Tang WJ. Molecular Bases for the Recognition of Short Peptide Substrates and Cysteine-Directed Modifications of Human Insulin-Degrading Enzyme. Biochemistry. 2008 Nov 6. PMID:18986166 doi:10.1021/bi801192h
  5. Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem. 2007 Aug 31;282(35):25453-63. Epub 2007 Jul 5. PMID:17613531 doi:10.1074/jbc.M701590200
Personal tools